Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALES: Pemetrexed + Carboplatin in SCLC
NCT00363415Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of pemetrexed in small cell lung cancer (SCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall Survival at 19.6 months. Started Aug 2006; status: completed.
02
Drugs
pemetrexed
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00363415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363415.